NEWS 6 FEED & ADDITIVE MAGAZINE July 2023 Neogen® Corp. launched Igenity® BeefXDairy, a new and novel leading genomic test for beef-on-dairy calves. According to the company's statement, genetic testing is critical to the efficient management and marketing of beef-on-dairy cattle, and the new Igenity BeefXDairy test provides producers with insight into key traits such as carcass quality, average daily gain, and the Igenity Terminal Index, which can then be used to market the calf's growth potential to buyers. The test will also allow buyers to receive breed composition data (e.g., percentage beef vs. percentage dairy) to help them best manage those cattle for optimal health and maximum growth. "Neogen is excited to be the first to offer up a commercial genomic tool for this growth cattle market," said Shelby Smith, Bovine Genomics Product Manager at Neogen. "This product offering is a massive step forward in helping to characterize beef-ondairy animals and allowing dairy producers, cattle buyers, and, ultimately, consumers of beef products to benefit. With increased DNA testing, we can enable improved quality, efficiency, and sustainability within beef production systems." Read more>> Neogen® launches DNA test for beef-on-dairy cattle dsm-firmenich, innovators in nutrition, health, and beauty, confirmed the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/ EBITDA multiple of 18x. Philip Eykerman, dsm-firmenich’s President Health, Nutrition & Care, said: “Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units. The Adare Biome teams will greatly help in driving our ‘Health from the Gut’ strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals. We are excited about the new opportunities this move will unlock, as dsm-firmenich’s strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world.” Tom Sellig, CEO of Adare Pharma Solutions, commented: “dsm-firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics. They have the infrastructure, together with strong commercialization and science capabilities, to scale the significant scientific research that we’ve achieved over the years. Moreover, dsm-firmenich’s purpose of bringing progress to life resonates strongly with the team. We look forward to contributing to the realization of this purpose as part of the dsm-firmenich family.” Read more>> dsm-firmenich completes acquisition of Adare Biome
RkJQdWJsaXNoZXIy MTUxNjkxNQ==